This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción B1N
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Bionomics Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.007 |
| 52 Week High | US$0.04 |
| 52 Week Low | US$0.0024 |
| Beta | 1.75 |
| 1 Month Change | 191.67% |
| 3 Month Change | 25.00% |
| 1 Year Change | -76.67% |
| 3 Year Change | -94.17% |
| 5 Year Change | -97.67% |
| Change since IPO | -91.25% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| B1N | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 0% | 2.1% | -1.0% |
| 1Y | -76.7% | -22.4% | 2.0% |
Rentabilidad vs. Industria: B1N underperformed the German Biotechs industry which returned -3.1% over the past year.
Rentabilidad vs. Mercado: B1N underperformed the German Market which returned 12.1% over the past year.
Volatilidad de los precios
| B1N volatility | |
|---|---|
| B1N Average Weekly Movement | 83.0% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: B1N's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: B1N's weekly volatility has increased from 59% to 83% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1996 | n/a | Spyros Papapetropoulos | www.bionomics.com.au |
Resumen de fundamentos de Bionomics Limited
| Estadísticas fundamentales de B1N | |
|---|---|
| Capitalización bursátil | €6.40m |
| Beneficios(TTM) | -€14.88m |
| Ingresos (TTM) | €3.59m |
1.8x
Ratio precio-ventas (PS)-0.4x
Ratio precio-beneficio (PE)¿Está B1N sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de B1N | |
|---|---|
| Ingresos | AU$6.02m |
| Coste de los ingresos | AU$19.80m |
| Beneficio bruto | -AU$13.79m |
| Otros gastos | AU$11.13m |
| Beneficios | -AU$24.91m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.017 |
| Margen bruto | -229.04% |
| Margen de beneficio neto | -413.94% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado B1N a largo plazo?
Ver rendimiento histórico y comparativa